Browse News
Filter News
Found 771,377 articles
-
Data from a Phase III trial of apraglutide for a type of short bowel syndrome with intestinal failure is expected by the end of the year. It is also in a Phase II study for acute graft-versus-host disease. -
Innate Pharma to Participate in Upcoming June 2023 Investor Conferences
5/23/2023
Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming conferences.
-
TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension
5/23/2023
TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.
-
Propanc Biopharma Announces Reverse Stock Split - May 23, 2023
5/23/2023
Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.
-
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023
5/23/2023
Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.
-
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
5/23/2023
Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.
-
Spago Nanomedical has Submitted Application to Start Tumorad(R) Clinical Phase I/IIa Study
5/23/2023
Spago Nanomedical AB announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia.
-
Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
5/23/2023
Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA.
-
OMRON Healthcare Celebrates 50 Years of Blood Pressure Monitor History
5/23/2023
OMRON Healthcare Co., Ltd. based in Muko City, Kyoto Prefecture, Japan, is proud to announce the celebration of its 50th anniversary in blood pressure monitor production this year.
-
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
5/23/2023
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis.
-
BioInvent Strengthens Management with Appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs
5/23/2023
BioInvent International AB announces the appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs.
-
Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation
5/23/2023
Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.
-
With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma. -
Sanofi and Regeneron reported positive results for the anti-inflammatory drug in a chronic obstructive pulmonary disease trial. The companies hope to see approval before a 2024 read-out of a second trial. -
The topical treatment Vyjuvek got the FDA’s greenlight, making it the first redosable gene therapy and the first therapeutic for the rare skin disease dystrophic epidermolysis bullosa. -
The 61-patient study met the primary endpoint of improved physiologic liver function and secondary endpoints, which included established non-alcoholic steatohepatitis biomarkers, Hepion reported Monday. -
ReCode–a New Contestant in the mRNA Race
5/22/2023
ReCode plans to use its SORT LNP genetic medicines delivery technology to treat CF and PCD patients who don’t respond to current treatments. -
The extensive discussion between the FDA’s advisory committee, company representatives and other interested parties could serve as a cautionary tale to developers of future gene therapies. -
More than $5 billion poured into the longevity space in 2022, and experts say the science is now primed to make a real difference in extending human healthspan. -
Blueprint Medicines, Opiant Pharmaceuticals and Lexicon Pharmaceuticals are all awaiting FDA decisions this week.